Ozempic vs Mounjaro: What Is the Difference?

Both Ozempic and Mounjaro are injectable medications for type 2 diabetes, and the ozempic vs mounjaro question is one of the most searched health comparisons right now. That interest makes sense. These drugs look similar on the surface: weekly injections, shared side effects, overlapping uses, yet they work through different mechanisms and deliver meaningfully different results for different people. This article breaks down what actually separates them, drawing on clinical trial data, real-world evidence, and practical access considerations, so you can have a more informed conversation with your prescriber.

Prescription disclaimer: Both Ozempic and Mounjaro are prescription-only medications. A consultation with a qualified healthcare professional is required before starting either treatment.

How ozempic and mounjaro work differently

Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics a gut hormone called glucagon-like peptide-1, which tells the pancreas to release insulin when blood sugar rises, slows digestion, and reduces appetite. One receptor, one mechanism, but one with a strong safety record and, critically, proven cardiovascular benefits.

Mounjaro (tirzepatide) does all of that and adds a second target: the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual-action approach amplifies appetite suppression and blood sugar control beyond what GLP-1 stimulation alone achieves. More receptor activation does not always mean a smoother ride, though; it also explains why Mounjaro tends to produce more gastrointestinal side effects at higher doses.

On the practical side, Ozempic uses a multi-dose pen requiring a new needle each week, while Mounjaro comes as a single-use pen that is simpler to operate. Patients with limited hand dexterity sometimes find the Mounjaro pen easier to handle, though it generates more waste. Both require refrigeration, though Ozempic can be stored at room temperature for up to 56 days once in use, compared with 21 days for Mounjaro, a detail that matters for frequent travellers.

Ozempic vs mounjaro: clinical efficacy and weight loss outcomes

The most-cited head-to-head comparison is the SURPASS-2 trial, published in 2021. It compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in over 1,870 adults with type 2 diabetes already taking metformin. Mounjaro reduced HbA1c by 2.0 to 2.3 percentage points depending on dose; Ozempic reduced it by roughly 1.9 percentage points at the 1 mg dose. Mounjaro also produced greater weight loss: an average of 16 to 25 lbs across doses, compared with approximately 12 lbs for Ozempic.

A caveat worth noting: Ozempic’s 2 mg dose was approved in March 2022, after SURPASS-2 was completed, so there is no fully comparable head-to-head data at equivalent maximum doses.

Real-world data published in 2024 supports the trial findings. An electronic health record study of 41,222 adults found that 81.8% of Mounjaro users lost at least 5% of body weight within 12 months, compared with 66.5% of Ozempic users. The average 12-month weight loss difference was approximately 6.9% in Mounjaro’s favour.

Where Ozempic holds a clear advantage is cardiovascular outcomes. The SELECT trial demonstrated a 20% reduction in heart attack, stroke, or cardiovascular death for high-risk patients taking semaglutide. Mounjaro’s cardiovascular outcome trials are ongoing, and no equivalent approval exists yet. For patients with established heart disease, this distinction can be decisive.

Neither Ozempic nor Mounjaro is licensed in the UK specifically for weight management under those brand names. The weight-loss-approved formulations are Wegovy (semaglutide, approved by the MHRA) and Zepbound (tirzepatide, which has received approval in some markets). If you are also weighing up Mounjaro against Wegovy, our guide to Mounjaro vs Wegovy covers that comparison in detail.

For a broader overview of injectable options across this category, see weight loss treatments available at Star Pharmacy.

Side effects and tolerability

Nausea, diarrhoea, vomiting, and constipation are common to both drugs and are worst during dose escalation. Both are started at a low dose and increased gradually over several weeks, which significantly reduces early side effects for most patients.

Mounjaro’s dual-receptor action does appear to produce somewhat higher rates of nausea and vomiting at peak doses. Discontinuation due to GI side effects runs at approximately 3 to 6.6% for Mounjaro users versus 3.1 to 3.8% for Ozempic users, based on published trial data.

Both drugs carry boxed warnings for possible thyroid C-cell tumours, including medullary thyroid carcinoma, based on animal studies , though this has not been confirmed in humans. Neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

A practical difference worth knowing: Mounjaro’s prescribing information includes a specific contraindication for patients with gastroparesis, because slowed gastric emptying compounds existing stomach motility problems. Ozempic’s warning on this point is less explicit, though caution is still warranted. If you have a history of severe gastrointestinal disease, discuss it with your prescriber before starting either medication.

BMI eligibility criteria: In the UK, weight management use of these drugs is generally considered for adults with a BMI of 30 or above, or 27 and above with weight-related comorbidities, in line with NICE guidance.

Cost and access in the UK

List prices vary by dose and pharmacy, but in practice, insurance and NHS coverage largely determine what patients pay rather than the listed price. Ozempic is available on the NHS for type 2 diabetes management. Mounjaro received NICE approval for type 2 diabetes in England in 2023, expanding NHS access.

For patients paying privately, manufacturer support programmes may reduce out-of-pocket costs. Both Novo Nordisk (Ozempic) and Eli Lilly (Mounjaro) have offered copay or savings cards in some markets, though eligibility criteria apply and programmes change.

It is also worth understanding that insurance or NHS approval for a diabetes indication does not automatically extend to weight loss use. Prior authorisation requirements, formulary tier placement, and step-therapy policies (where an insurer may require a trial of an older medication first) can all influence which drug a patient ends up taking , sometimes regardless of clinical preference.

Drug shortages have also been a real-world factor in recent years, affecting prescribing decisions in ways that clinical trial data cannot anticipate.

Frequently asked questions

Can I take ozempic and mounjaro at the same time?

No. Combining Ozempic and Mounjaro is not recommended. Both drugs affect the same hormonal pathways, and using them together significantly raises the risk of serious side effects, including severe nausea, hypoglycaemia, and gastrointestinal complications. Your prescriber will choose one or the other based on your clinical profile.

Is mounjaro stronger than ozempic?

Mounjaro generally produces greater HbA1c reduction and more weight loss than Ozempic in clinical trials and real-world studies. However, “stronger” does not mean “better for everyone.” Ozempic has proven cardiovascular benefits that Mounjaro currently lacks, and some patients tolerate Ozempic better due to fewer GI side effects at comparable doses.

Can I switch from ozempic to mounjaro?

Switching is possible, but it requires restarting the dose escalation process from the beginning on the new medication. There is no direct dose conversion between the two. The transition typically takes four to eight weeks to reach a therapeutic dose, and close monitoring by your prescriber during this period is important.

Which drug is better for weight loss?

Mounjaro produces greater average weight loss in both clinical trials and real-world data. In SURPASS-2, Mounjaro users lost 16 to 25 lbs on average versus approximately 12 lbs for Ozempic. In a 2024 real-world study, 81.8% of Mounjaro users lost at least 5% of body weight within a year, compared with 66.5% of Ozempic users.

Are these drugs available in the UK?

Yes. Ozempic is available on the NHS for type 2 diabetes. Mounjaro is also approved for type 2 diabetes in England following NICE guidance issued in 2023. Wegovy (semaglutide) is separately approved for weight management. Access via prescription is required for all of these medications.

Conclusion

Ozempic and Mounjaro are not interchangeable, and neither is universally superior. Mounjaro’s dual-receptor mechanism produces greater HbA1c reduction and more weight loss for most patients. Ozempic has a proven track record in cardiovascular risk reduction that Mounjaro has not yet matched. Tolerability, cost, NHS eligibility, and your own medical history all shape which one makes more sense for you.If you are considering either medication, the next step is a consultation with a prescriber who can weigh up your cardiovascular risk, GI history, and treatment goals rather than applying a one-size-fits-all answer. To explore your options and speak with a registered prescriber, visit Star Pharmacy for Mounjaro treatment.